DTM™ Spinal Cord Stimulation Using the Medtronic Intellis™ Platform Shows Superior Back Pain Relief Compared to Conventional SCS Therapy in an RCT

DUBLIN, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT) today announced three-month results from a large, multicenter randomized controlled trial (RCT) showing statistically significant (p=0.0009) and superior back pain relief with Differential Target Multiplexed (DTM) Spinal Cord Stimulation (SCS) compared to conventional SCS.